## Matthew Lloyd D

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4703911/publications.pdf

Version: 2024-02-01

82 papers 3,087 citations

32 h-index 53 g-index

84 all docs

84 docs citations

84 times ranked 2887 citing authors

#	Article	IF	CITATIONS
1	Selenium Status in Diet Affects Acetaminophen-Induced Hepatotoxicity <i>via</i> li> Interruption of Redox Environment. Antioxidants and Redox Signaling, 2021, 34, 1355-1367.	5.4	13
2	Racemases and epimerases operating through a 1,1-proton transfer mechanism: reactivity, mechanism and inhibition. Chemical Society Reviews, 2021, 50, 5952-5984.	38.1	9
3	UVA-Triggered Drug Release and Photo-Protection of Skin. Frontiers in Cell and Developmental Biology, 2021, 9, 598717.	3.7	16
4	Steady-state enzyme kinetics. Biochemist, 2021, 43, 40-45.	0.5	3
5	High-Throughput Screening for the Discovery of Enzyme Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 10742-10772.	6.4	47
6	Identification of novel small-molecule inhibitors of $\hat{l}_{\pm}$ -methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships. Bioorganic Chemistry, 2019, 92, 103264.	4.1	11
7	Novel 2-arylthiopropanoyl-CoA inhibitors of $\hat{l}_{\pm}$ -methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents. Bioorganic Chemistry, 2019, 92, 103263.	4.1	9
8	Long-wavelength TCF-based fluorescence probes for the detection and intracellular imaging of biological thiols. Chemical Communications, 2018, 54, 4786-4789.	4.1	68
9	Structure-activity relationships of rationally designed AMACR 1A inhibitors. Bioorganic Chemistry, 2018, 79, 145-154.	4.1	8
10	A novel colorimetric assay for $\hat{l}$ ±-methylacyl-CoA racemase 1A (AMACR; P504S) utilizing the elimination of 2,4-dinitrophenolate. Chemical Communications, 2017, 53, 5087-5090.	4.1	18
11	Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity. Journal of Medicinal Chemistry, 2017, 60, 814-820.	6.4	40
12	Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases. European Journal of Medicinal Chemistry, 2016, 118, 316-327.	5.5	24
13	The different catalytic roles of the metal-binding ligands in human 4-hydroxyphenylpyruvate dioxygenase. Biochemical Journal, 2016, 473, 1179-1189.	3.7	13
14	Electro-Engineered Polymeric Films for the Development of Sensitive Aptasensors for Prostate Cancer Marker Detection. ACS Sensors, 2016, 1, 1308-1314.	7.8	35
15	A study on the AMACR catalysed elimination reaction and its application to inhibitor testing. Organic and Biomolecular Chemistry, 2016, 14, 612-622.	2.8	10
16	Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases. Bioorganic and Medicinal Chemistry, 2015, 23, 3013-3032.	3.0	36
17	Initial development of a cytotoxic amino-seco-CBI warhead for delivery by prodrug systems. Bioorganic and Medicinal Chemistry, 2015, 23, 3481-3489.	3.0	2
18	Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro. Bioorganic and Medicinal Chemistry, 2015, 23, 5891-5908.	3.0	26

#	Article	IF	Citations
19	A study on the chiral inversion of mandelic acid in humans. Organic and Biomolecular Chemistry, 2014, 12, 6737-6744.	2.8	13
20	The perils of rational design – unexpected irreversible elimination of fluoride from 3-fluoro-2-methylacyl-CoA esters catalysed by α-methylacyl-CoA racemase (AMACR; P504S). Chemical Communications, 2014, 50, 14164-14166.	4.1	9
21	One-pot tandem Hurtley–retro-Claisen–cyclisation reactions in the synthesis of 3-substituted analogues of 5-aminoisoquinolin-1-one (5-AIQ), a water-soluble inhibitor of PARPs. Bioorganic and Medicinal Chemistry, 2013, 21, 5218-5227.	3.0	19
22	Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases. ACS Medicinal Chemistry Letters, 2013, 4, 1173-1177.	2.8	35
23	Hydrolysis of ibuprofenoyl-CoA and other 2-APA-CoA esters by human acyl-CoA thioesterases-1 and -2 and their possible role in the chiral inversion of profens. Biochemical Pharmacology, 2013, 86, 1621-1625.	4.4	12
24	α-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S. Progress in Lipid Research, 2013, 52, 220-230.	11.6	75
25	New aminocyclitols with quaternary stereocentres via acylnitroso cycloaddition with an ipso,ortho arene dihydrodiol. Tetrahedron, 2013, 69, 5989-5997.	1.9	38
26	Chiral inversion of 2-arylpropionyl-CoA esters by human α-methylacyl-CoA racemase 1A (P504S)—a potential mechanism for the anti-cancer effects of ibuprofen. Chemical Communications, 2011, 47, 7332.	4.1	38
27	5-Benzamidoisoquinolin-1-ones and 5-(ω-Carboxyalkyl)isoquinolin-1-ones as Isoform-Selective Inhibitors of Poly(ADP-ribose) Polymerase 2 (PARP-2). Journal of Medicinal Chemistry, 2011, 54, 2049-2059.	6.4	46
28	N3-Alkylation during formation of quinazolin-4-ones from condensation of anthranilamides and orthoamides. Organic and Biomolecular Chemistry, 2011, 9, 6089.	2.8	17
29	Synthesis of 4-alkyl-, 4-aryl- and 4-arylamino-5-aminoisoquinolin-1-ones and identification of a new PARP-2 selective inhibitor. Organic and Biomolecular Chemistry, 2011, 9, 881-891.	2.8	14
30	"lnosaminoacids†novel inositol†amino acid hybrid structures accessed by microbial arene oxidation. Chemical Communications, 2011, 47, 4799.	4.1	47
31	S-2-Amino-4-cyanobutanoic acid ( $\hat{l}^2$ -cyanomethyl-l-Ala) as an atom-efficient solubilising synthon for l-glutamine. Tetrahedron Letters, 2011, 52, 5311-5314.	1.4	0
32	Cloning, purification, crystallization and preliminary crystallographic analysis of the human histone deacetylase sirtuin 1. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 461-463.	0.7	1
33	Structures of Human Carbonic Anhydrase II/Inhibitor Complexes Reveal a Second Binding Site for Steroidal and Nonsteroidal Inhibitors <sup>,</sup> . Biochemistry, 2010, 49, 3464-3476.	2.5	18
34	Unexpected stereoselective exchange of straight-chain fatty acyl-CoA î±-protons by human î±-methylacyl-CoA racemase 1A (P504S). Chemical Communications, 2010, 46, 3348.	4.1	12
35	4-Substituted 5-nitroisoquinolin-1-ones from intramolecular Pd-catalysed reaction of N-(2-alkenyl)-2-halo-3-nitrobenzamides. Tetrahedron, 2009, 65, 4751-4765.	1.9	14
36	Synthesis of 2-(4-carboxybutenyl)- and 2-(4-carboxybutynyl)-cyclopentene-1-carboxamides. Tetrahedron, 2009, 65, 8176-8184.	1.9	10

#	Article	IF	CITATIONS
37	Synthesis and use of isotope-labelled substrates for a mechanistic study on human α-methylacyl-CoA racemase 1A (AMACR; P504S). Organic and Biomolecular Chemistry, 2009, 7, 543-552.	2.8	35
38	Design, Synthesis, and Evaluation in Vitro of Quinoline-8-carboxamides, a New Class of Poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) Inhibitor. Journal of Medicinal Chemistry, 2009, 52, 868-877.	6.4	76
39	αâ€Methylacylâ€CoA racemaseâ€f–â€fan â€~obscure' metabolic enzyme takes centre stage. FEBS Journal, 1089-1102.	2008, 27 4.7	5. 98
40	A microtitre plate assay for measuring glycosidase activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 131-135.	5.2	11
41	Characterisation of recombinant human fatty aldehyde dehydrogenase: Implications for SjĶgren-Larsson syndrome. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 584-590.	5.2	14
42	Dr Brian Gibberd (1931–2006): a pioneering clinician in Refsum's disease. Biochemical Society Transactions, 2007, 35, 862-864.	3.4	2
43	Synthesis and conformational and configurational studies of diastereoisomeric O-protected 4-(arylsulfonimidoyl)butane-1,2,3-triols. Tetrahedron, 2007, 63, 12601-12607.	1.9	2
44	Crystal structure of human carbonic anhydrase II at $1.95 {\rm AA}$ resolution in complex with 667-coumate, a novel anti-cancer agent. Biochemical Journal, 2005, 385, 715-720.	3.7	55
45	Studies on the specificity of unprocessed and mature forms of phytanoyl-CoA 2-hydroxylase and mutation of the iron binding ligands. Journal of Lipid Research, 2005, 46, 1660-1667.	4.2	15
46	First Crystal Structures of Human Carbonic Anhydrase II in Complex with Dual Aromataseâ^'Steroid Sulfatase Inhibitorsâ€,‡. Biochemistry, 2005, 44, 6858-6866.	2.5	42
47	The advantages and limitations of protein crystal structures. Trends in Pharmacological Sciences, 2005, 26, 10-14.	8.7	91
48	Controlling the Substrate Selectivity of Deacetoxycephalosporin/deacetylcephalosporin C Synthase. Journal of Biological Chemistry, 2004, 279, 15420-15426.	3.4	32
49	Role of Phytanoyl-CoA 2-Hydroxylase in Phytanic Acid Metabolism. Advances in Experimental Medicine and Biology, 2004, 544, 303-304.	1.6	1
50	The kinetic properties of various R258 mutants of deacetoxycephalosporin C synthase. FEBS Journal, 2003, 270, 1301-1307.	0.2	10
51	The chemical biology of branched-chain lipid metabolism. Progress in Lipid Research, 2003, 42, 359-376.	11.6	71
52	Phytanic acid alpha-oxidation, new insights into an old problem: a review. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 119-135.	2.4	65
53	Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. Journal of Lipid Research, 2003, 44, 1481-1488.	4.2	36
54	Active Site Mutations of Recombinant Deacetoxycephalosporin C Synthase. Biochemical and Biophysical Research Communications, 2002, 292, 66-70.	2.1	20

#	Article	IF	Citations
55	Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. Journal of Neurochemistry, 2002, 80, 727-735.	3.9	182
56	Utilization of Sterol Carrier Protein-2 by Phytanoyl-CoA 2-Hydroxylase in the Peroxisomal α Oxidation of Phytanic Acid. Chemistry and Biology, 2002, 9, 597-605.	6.0	51
57	The role of arginine residues in substrate binding and catalysis by deacetoxycephalosporin C synthase. FEBS Journal, 2002, 269, 2735-2739.	0.2	27
58	Kinetic and crystallographic studies on deacetoxycephalosporin C synthase (DAOCS). Journal of Molecular Biology, 2001, 308, 937-948.	4.2	99
59	â€~Chemical co-substrate rescue' of phytanoyl-CoA 2-hydroxylase mutants causing Refsum's Disease. Chemical Communications, 2001, , 972-973.	4.1	27
60	Probing the penicillin sidechain selectivity of recombinant deacetoxycephalosporin C synthase. Cellular and Molecular Life Sciences, 2001, 58, 835-843.	5.4	27
61	Contrasting fates for $6 \cdot \hat{l} \pm -methylpenicillin$ N upon oxidation by deacetoxycephalosporin C synthase (DAOCS) and deacetoxy/deacetylcephalosporin C synthase (DAOC/DACS). Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2511-2514.	2.2	5
62	Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-Coenzyme A. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2545-2548.	2.2	23
63	Alteration of the Co-substrate Selectivity of Deacetoxycephalosporin C Synthase. Journal of Biological Chemistry, 2001, 276, 18290-18295.	3.4	35
64	Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease. Human Molecular Genetics, 2001, 10, 1971-1982.	2.9	64
65	The Effect of Cysteine Mutations on Recombinant Deacetoxycephalosporin C Synthase from S. clavuligerus. Biochemical and Biophysical Research Communications, 2000, 267, 445-448.	2.1	28
66	The iron(II) and 2-oxoacid-dependent dioxygenases and their role in metabolism (1967 to 1999). Natural Product Reports, 2000, 17, 367-383.	10.3	175
67	Product-substrate engineering by bacteria: Studies on clavaminate synthase, a trifunctional dioxygenase. Tetrahedron, 1999, 55, 10201-10220.	1.9	52
68	Studies on the active site of deacetoxycephalosporin C synthase. Journal of Molecular Biology, 1999, 287, 943-960.	4.2	111
69	Structure of a cephalosporin synthase. Nature, 1998, 394, 805-809.	27.8	344
70	Studies on non-haem ferrous-dependent oxygenases and oxidases. Biochemical Society Transactions, 1997, 25, 86-90.	3.4	7
71	Chemo-enzymatic synthesis of bicyclic $\hat{l}^3$ -lactams using clavaminic acid synthase. Tetrahedron, 1997, 53, 7011-7020.	1.9	13
72	Competing pathways in the oxidation of -3-ethylidine cephalosporin C by the enzyme deacetoxycephalosporin C synthase (DAOCS). Bioorganic and Medicinal Chemistry Letters, 1997, 7, 593-596.	2.2	2

#	Article	IF	CITATION
73	Fast Staining and Destaining of Sodium Dodecyl Sulfate–Polyacrylamide Gels. Analytical Biochemistry, 1996, 241, 139-140.	2.4	4
74	Adipoyl-6-aminopenicillanic acid is a substrate for deacetoxycephalosporin C synthase (DAOCS). Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1579-1584.	2.2	14
75	Crystallization and preliminary Xâ€ray diffraction analysis of recombinant pentalenene synthase. Protein Science, 1995, 4, 2436-2438.	7.6	11
76	Expression in Escherichia coli of a clavaminic acid synthase isozyme: A trifunctional oxygenase involved in clavulanic acid biosynthesis. Tetrahedron, 1994, 50, 8737-8748.	1.9	25
77	Pentalenene Synthase. Purification, Molecular Cloning, Sequencing, and High-Level Expression in Escherichia coli of a Terpenoid Cyclase from Streptomyces UC5319. Biochemistry, 1994, 33, 5846-5857.	2.5	142
78	Substrate analogue studies on clavaminic acid synthase. Journal of the Chemical Society Chemical Communications, 1993, , 1694.	2.0	11
79	A substrate analogue study on clavaminic acid synthase: possible clues to the biosynthetic origin of proclavamic acid. Journal of the Chemical Society Chemical Communications, 1993, , 500.	2.0	42
80	Enzymatic synthesis of bicyclic $\hat{I}^3$ -lactams using clavaminic acid synthase. Journal of the Chemical Society Chemical Communications, 1992, , 877-879.	2.0	9
81	Isolation of dihydroclavaminic acid, an intermediate in the biosynthesis of clavulanic acid. Tetrahedron, 1991, 47, 4089-4100.	1.9	53
82	Isolation of an intermediate in clavulanic acid biosynthesis. Journal of the Chemical Society Chemical Communications, 1990, , 617.	2.0	22